Literature DB >> 11769821

Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug.

H C Fox1, A C Parrott, J J Turner.   

Abstract

Previous research has shown drug-free Ecstasy users to demonstrate selective cognitive impairment. However, there seems to be a degree of individual variation in the occurrence of such deficits. The present study aimed to assess whether these cognitive deficits are related to an awareness of problematic Ecstasy use, or to past drug dosage. Twenty regular Ecstasy users who reported experiencing Ecstasy-related problems were compared with 20 Ecstasy users who had not reported any previous problems. The two groups displayed similar past histories in relation to a range of illicit drugs, and were divided into low, medium and high users. The controls comprised 20 illicit recreational drug users who had never taken Ecstasy. Executive task measures comprised the Tower of London (TOL), the Wisconsin Card Sorting Task (WCST) and spatial working memory. Immediate and delayed word recall, matched verbal recognition and recall and simple reaction time were also included. Both Ecstasy groups performed significantly worse than controls on two executive measures: TOL planning time and spatial working memory score. There were no differences in cognitive impairment between the Ecstasy users who complained of problems and those who did not. In both groups, decrement on executive tasks was demonstrated as a function of previous drug dose. The study confirms that heavy Ecstasy polydrug use may culminate in selective executive deficits. It also demonstrates that two differently self-perceived Ecstasy groups showed similar cognitive impairment, despite only one group complaining of problems. Because all Ecstasy participants also consumed a range of other illicit drugs, the results are reflective of Ecstasy polydrug use in individuals who use Ecstasy as a drug of preference.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11769821     DOI: 10.1177/026988110101500406

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  34 in total

1.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

2.  Response to: Parrott AC, Buchanan T, Heffernan TM, Scholey A, Ling J, Rodgers J (2003) Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology 167(4):449-450.

Authors:  H R Sumnall; L Jerome; R Doblin; M C Mithoefer
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

Review 3.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

Review 4.  Gene-environment interplay in alcoholism and other substance abuse disorders: expressions of heritability and factors influencing vulnerability.

Authors:  Tomas Palomo; R M Kostrzewa; R J Beninger; T Archer
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

5.  The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory.

Authors:  Catharine Montgomery; John E Fisk; Russell Newcombe; Phillip N Murphy
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

6.  Profile of executive deficits in cocaine and heroin polysubstance users: common and differential effects on separate executive components.

Authors:  Antonio Verdejo-García; Miguel Pérez-García
Journal:  Psychopharmacology (Berl)       Date:  2006-11-29       Impact factor: 4.530

7.  Chronic cognitive impairment in users of 'ecstasy' and cannabis.

Authors:  Anthony Klugman; John Gruzelier
Journal:  World Psychiatry       Date:  2003-10       Impact factor: 49.548

Review 8.  MDMA use and neurocognition: a meta-analytic review.

Authors:  Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton
Journal:  Psychopharmacology (Berl)       Date:  2006-11-03       Impact factor: 4.530

9.  Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.

Authors:  Rebecca D Crean; Sophia A Davis; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

10.  Reward-related decision-making deficits and elevated impulsivity among MDMA and other drug users.

Authors:  Karen L Hanson; Monica Luciana; Kristin Sullwold
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.